These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36660471)

  • 1. Barriers to Hepatitis C Virus Care and How Federally Qualified Health Centers Can Improve Patient Access to Treatment.
    Lam D; Wong RJ; Tessier A; Zapata Y; Saldana E; Gish RG
    Gastroenterology Res; 2022 Dec; 15(6):343-352. PubMed ID: 36660471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center.
    Downes JM; Donovan A; McAdam-Marx C
    J Am Pharm Assoc (2003); 2022; 62(5):1596-1605. PubMed ID: 35595639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
    Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
    Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans.
    Beck KR; Kim NJ; Khalili M
    Ann Hepatol; 2018; 17(3):413-418. PubMed ID: 29735789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.
    Liu L; Daftary MN; Alzahrani MS; Ohanele C; Maneno MK
    J Natl Med Assoc; 2021 Apr; 113(2):147-157. PubMed ID: 32868101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center.
    Rojas SA; Godino JG; Northrup A; Khasira M; Tam A; Asmus L; Frenette C; Ramers CB
    Hepatol Commun; 2021 Mar; 5(3):412-423. PubMed ID: 33681676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.
    Collins LF; Chan A; Zheng J; Chow SC; Wilder JM; Muir AJ; Naggie S
    Open Forum Infect Dis; 2018 Jan; 5(1):ofx264. PubMed ID: 29308413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
    Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
    Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of asthma medication adherence rates and strategies to improve adherence in the underserved population at a Federally Qualified Health Center.
    Bidwal M; Lor K; Yu J; Ip E
    Res Social Adm Pharm; 2017; 13(4):759-766. PubMed ID: 27595427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 11. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
    Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    Javanbakht M; Archer R; Klausner J
    PLoS One; 2020; 15(11):e0241615. PubMed ID: 33147293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic.
    Malespin M; Harris C; Kanar O; Jackman K; Smotherman C; Johnston A; Ferm J; de Melo SW; Scolapio JS; Nelson DR; Cotler SJ
    Ann Hepatol; 2019; 18(2):304-309. PubMed ID: 31053544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Treatment Cascade in a Federally Qualified Health Center.
    Hachey DM; Holmes JT; Aubuchon-Endsley NL
    J Community Health; 2020 Apr; 45(2):264-268. PubMed ID: 31512110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
    Jung J; Du P; Feldman R; Kong L; Riley T
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
    Wong RJ; Jain MK; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Thamer M
    Am J Gastroenterol; 2018 Sep; 113(9):1329-1338. PubMed ID: 29523864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short article: Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Sims OT; Guo Y; Shoreibah MG; Venkata K; Fitzmorris P; Kommineni V; Romano J; Massoud OI
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1219-1222. PubMed ID: 28857899
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.